Gepostet in 2019.03.20. 00:34
DARMSTADT, Germany and NEW YORK, March 19, 2019 /PRNewswire/ — Not intended for UK-based media Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib,* a poly (ADP-ribose) polymerase (PARP) inhibitor, versus an active comparator in treatment-naïve patients with locally advanced or metastatic ovarian cancer (Stage III or Stage IV). The alliance has notified ...
Gepostet in der Kategorie Wirtschaft (Anzahl der ansichten:) 5